Form 4: Adverum Director Sells All Holdings in Eli Lilly Merger

Adverum Biotechnologies director Mark L. Lupher, Jr. disposed of all common stock and stock options following the company's acquisition by Eli Lilly and Company.

Summary

• Mark L. Lupher, Jr., a director of Adverum Biotechnologies, Inc. (ADVM), reported changes in his beneficial ownership of the company's securities.
• These transactions occurred on December 9, 2025, as a direct result of the merger between Adverum Biotechnologies, Inc. and Flying Tigers Acquisition Corporation, a wholly-owned subsidiary of Eli Lilly and Company.
• Adverum Biotechnologies, Inc. is now a wholly-owned subsidiary of Eli Lilly and Company.
• As part of the merger, tendering stockholders received $3.56 per share in cash (Cash Consideration) and one non-tradable Contingent Value Right (CVR) per share.
• Each CVR represents the contractual right to receive up to two contingent cash payments, totaling up to an aggregate of $8.91 per CVR, upon the achievement of specified milestones.
• Mr. Lupher disposed of 13,000 shares of Adverum Common Stock, resulting in zero shares beneficially owned after the transaction.
• Stock options with an exercise price equal to or greater than the $3.56 Cash Consideration were fully vested prior to the merger and subsequently cancelled for no consideration.
• Stock options with an exercise price less than the $3.56 Cash Consideration were cancelled in exchange for a cash payment and CVRs. For example, an option for 10,450 shares with an exercise price of $2.32 resulted in a cash payment of $12,958 and 10,450 CVRs.
• Following these transactions, Mr. Lupher beneficially owns zero derivative securities.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a major corporate strategic event (merger), which is generally a positive outcome for the acquiring and acquired entities. While some option holders faced cancellation without consideration, the overall transaction provided cash and potential future value (CVRs) to shareholders, indicating a structured and executed strategic move.

Positives

• Adverum Biotechnologies, Inc. stockholders received a cash consideration of $3.56 per share as part of the merger.
• Stockholders also received Contingent Value Rights (CVRs) with potential future cash payments up to an aggregate of $8.91 per CVR, offering additional upside potential.
• Cash-out stock options with exercise prices below the cash consideration were monetized, providing a cash payment and CVRs to holders.

Negatives

• Stock options with exercise prices equal to or greater than the $3.56 Cash Consideration were cancelled for no consideration, resulting in a loss for holders of these 'out-of-the-money' options.
• Adverum Biotechnologies, Inc. is no longer an independent publicly traded entity, transitioning to a wholly-owned subsidiary of Eli Lilly and Company.

Risks

• The value of the Contingent Value Rights (CVRs) is dependent on the achievement of specified milestones, meaning there is no guarantee of receiving the full potential payment of $8.91 per CVR.
• The CVRs are non-tradable, which limits liquidity for holders and their ability to sell or transfer these rights.

Future Outlook

Adverum Biotechnologies, Inc. will operate as a wholly-owned subsidiary of Eli Lilly and Company. Its future financial performance and strategic direction will be integrated within Eli Lilly's broader operations. The potential for additional payments to former Adverum shareholders depends on the achievement of specified milestones related to the Contingent Value Rights.

Industry Context

This acquisition by Eli Lilly and Company of Adverum Biotechnologies, Inc. is consistent with the ongoing trend of consolidation within the biotechnology and pharmaceutical sectors. Larger pharmaceutical companies frequently acquire smaller biotech firms to enhance their pipelines, gain access to innovative technologies, or expand into specialized therapeutic areas, such as gene therapy.

Comparison to Industry Standards

• The merger's structure, combining an upfront cash payment with Contingent Value Rights (CVRs), is a common approach in biotech mergers and acquisitions. This mechanism helps bridge valuation gaps and aligns incentives for future performance, similar to deals such as Gilead Sciences' acquisition of Immunomedics or Bristol Myers Squibb's acquisition of MyoKardia.
• The cancellation of out-of-the-money stock options (where the exercise price exceeds the acquisition price) for no consideration is standard practice in corporate mergers and acquisitions.

Corporate Governance

Stakeholder Impact

• Shareholders (former): Received cash and CVRs for their shares, with varying outcomes for option holders depending on their exercise price.
• Employees (Adverum): Now part of Eli Lilly and Company, which may impact their roles, benefits, and corporate culture.
• Management (Adverum): Mark L. Lupher, Jr. (director) disposed of all beneficial securities, indicating a change in his direct financial relationship with the company's public ownership structure.

Next Steps

• Monitoring the achievement of specified milestones for the Contingent Value Rights (CVRs) to trigger potential future cash payments.
• Integration of Adverum Biotechnologies, Inc.'s operations and assets into Eli Lilly and Company.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Eli Lilly, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Contingent Value Rights, CVR, Tender Offer, Beneficial Ownership